Abstract: Objective To investigate the polymorphism of programmed death-ligand 1（PD-L1） gene in susceptibility and prognosis of patients with hepatocellular carcinoma（HCC）. Methods 100 patients with HCC and 100 healthy persons were recruited in our hospital between January 2010 and June 2015. The peripheral blood were collected to assay the single nucleotide polymorphisms（SNP）,including rs4143185,rs17718883 and rs28906583,of PD-L1 gene by direct sequencing and polymerase chain reaction-single strand conformation polymorphism（PCR-SSCP）. Results The AC heterozygous mutation gene of rs2890658 reduced the risk of liver cancer susceptibility （OR=0.391,P<0.05）,and the CG heterozygous mutation of rs17718883 also reduced the risk of liver cancer susceptibility （OR=0.009,P<0.05）;the median survival times of 3 genotypes （AA,AC and CC） of rs2890658 were 18（15,21） m,20（16,22） m and 19（15,21） m,no significant differences among（P>0.05）;the median survival time in combination of genotype AC and CC was 20（16,23） m,much longer than carrying genotype AA（P<0.05）;there were significantly differences among survival times in individuals carrying CC,GC and GC of rs4143185 gene [16（13,19） m,20（15,23） m and 17（15,21） m,respectively,P<0.05],and the survival time in persons carrying combination of CG and GG was 21（17,24） m,much longer than those carrying CC（P<0.05）;COX regression analysis showed that patients carrying mutant genes of rs4143185 had a good prognosis （HR<1,P<0.05）. Conclusion The detection of blood PD-L1 gene polymorphism might be useful in clinical practice in screening individuals with high risk of HCC susceptibility and in forecasting the prognosis of patients with HCC.

Key words: Hepatoma, Programmed death-ligand 1, Single nucleotide polymorphisms, Susceptibility, Prognosis